Jillian Glenda Baker

Jillian Glenda Baker

Auto-generated profile, based on publicly available information

Jillian Glenda Baker

University of Nottingham

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2008 in Nature
Verified
Journal Article
Closed access
PDF file
TWTony Warne
Tony Warne
MSMaria J. Serrano-Vega
Maria J. Serrano-Vega
JBJillian G. Baker
Jillian G. Baker
RMRouslan Moukhametzianov
Rouslan Moukhametzianov
PEPatricia C. Edwards
Patricia C. Edwards
GSGebhard F. X. Schertler
Gebhard F. X. Schertler

12 January 2011 in Nature
Verified
Journal Article
Open access
PDF file
TWTony Warne
Tony Warne
RMRouslan Moukhametzianov
Rouslan Moukhametzianov
JBJillian G. Baker
Jillian G. Baker
RNRony Nehmé
Rony Nehmé
PEPatricia C. Edwards
Patricia C. Edwards
CTChristopher G. Tate
Christopher G. Tate
Two papers by Brian Kobilka and colleagues describe the X-ray crystal structure of the human β2 adrenergic receptor (β2AR) bound to various agonists. β2AR is a member of the G protein coupled receptor (GPCR) family of membrane-spanning receptors that sense molecules outside the cell and activate internal signalling pathways. With a ubiquitous role in human physiology, GPCRs are prime targets for drug discovery. A third paper by Christopher Tate and his team describes crystal structures of a similar GPCR, the turkey β1-adrenergic receptor (β1AR), bound to full and partial agonists. Together, these new structures reveal the subtle structural changes that accompany agonist binding, showing how binding events inside and outside the cell membrane stabilize the receptor's active state. Agonist binding to β1AR is shown to induce a contraction of the catecholamine-binding pocket relative to the antagonist-bound receptor, and molecular-dynamics simulations of the β2AR agonist complex suggest that the agonist-bound active state spontaneously relaxes to an inactive-like state in the absence of a G protein. Here, the X-ray crystal structure of the β1 adrenergic receptor, a G-protein-coupled receptor, bound to four small molecules that either act as full agonists or partial agonists is solved. The structures show that agonist binding induces a contraction of the catecholamine-binding pocket relative to the antagonist-bound receptor. This work reveals the pharmacological differences between different ligand classes, which should facilitate the structure-based design of new drugs with predictable efficacies. β-adrenergic receptors (βARs) are G-protein-coupled receptors (GPCRs) that activate intracellular G proteins upon binding catecholamine agonist ligands such as adrenaline and noradrenaline1,2. Synthetic ligands have been developed that either activate or inhibit βARs for the treatment of asthma, hypertension or cardiac dysfunction. These ligands are classified as either full agonists, partial agonists or antagonists, depending on whether the cellular response is similar to that of the native ligand, reduced or inhibited, respectively. However, the structural basis for these different ligand efficacies is unknown. Here we present four crystal structures of the thermostabilized turkey (Meleagris gallopavo) β1-adrenergic receptor (β1AR-m23) bound to the full agonists carmoterol and isoprenaline and the partial agonists salbutamol and dobutamine. In each case, agonist binding induces a 1 Å contraction of the catecholamine-binding pocket relative to the antagonist bound receptor. Full agonists can form hydrogen bonds with two conserved serine residues in transmembrane helix 5 (Ser5.42 and Ser5.46), but partial agonists only interact with Ser5.42 (superscripts refer to Ballesteros–Weinstein numbering3). The structures provide an understanding of the pharmacological differences between different ligand classes, illuminating how GPCRs function and providing a solid foundation for the structure-based design of novel ligands with predictable efficacies.

1 February 2005 in British Journal of Pharmacology
Verified
Journal Article
Closed access
PDF file
JBJillian G Baker
Jillian G Baker

7 June 2010 in British Journal of Pharmacology
Verified
Journal Article
Open access
PDF file
JBJillian G Baker
Jillian G Baker
Background and purpose: There are two important properties of receptor–ligand interactions: affinity (the ability of the ligand to bind to the receptor) and efficacy (the ability of the receptor–ligand complex to induce a response). Ligands are classified as agonists or antagonists depending on whether or not they have efficacy. In theory, it is possible to develop selective agonists based on selective affinity, selective intrinsic efficacy or both. This study examined the affinity and intrinsic efficacy of 31 β‐adrenoceptor agonists at the three human β‐adrenoceptors to determine whether the current agonists are subtype selective because of affinity or intrinsic efficacy.Experimental approach: Stable clonal CHO‐K1 cell lines, transfected with either the human β1, β2or β3‐adrenoceptor, were used, and whole‐cell [3H]‐CGP 12177 radioligand binding and [3H]‐cAMP accumulation were measured.Key results: Several agonists were found to be highly subtype selective because of selective affinity (e.g. salmeterol and formoterol, for the β2‐adrenoceptor over the β1or β3), while others (e.g. isoprenaline) had little affinity–selectivity. However, the intrinsic efficacy of salmeterol, formoterol and isoprenaline was similar across all three receptor subtypes. Other ligands (e.g. denopamine for β1; clenbuterol, AZ 40140d, salbutamol for β2) were found to have subtype‐selective intrinsic efficacy. Several ligands appeared to activate two agonist conformations of the β1‐ and β3‐adrenoceptors.Conclusions and implications: There are agonists with subtype selectivity based upon both selective affinity and selective intrinsic efficacy. Therefore, there is scope to develop better selective agonists based upon both selective affinity and selective intrinsic efficacy.This article is commented on by Kenakin, pp. 1045–1047 of this issue. To view this commentary visithttp://dx.doi.org/10.1111/j.1476‐5381.2010.00764.x

1 December 2003 in Molecular Pharmacology
Verified
Journal Article
Closed access
PDF file
JBJillian G. Baker
Jillian G. Baker
IHIan P. Hall
Ian P. Hall
SHStephen Hill
Stephen Hill
β-Blockers have beneficial effects in heart failure, although the underlying mechanism is unknown. β2-Adrenoceptors, however, are proportionally higher in the failing human heart. This study shows several clinically used β-blockers are agonists at the human β2-adrenoceptor. Although these agonist effects were small at the cAMP level, they were substantial at the level of cAMP response element (CRE)-mediated gene transcription. Some of the effects of “β-blockers” seen in heart failure may be related to the β2-agonist actions of these compounds. CRE-gene transcription responses to β2-agonists, forskolin, and cAMP-analogs were sensitive to p42/44-mitogen-activated protein (MAP) kinase pathway inhibitors. p42/44-MAP kinase activation was also shown directly by western blotting and enzyme-linked immunosorbent assay techniques. N-[2-(4-bromocinnamylamino)ethyl]-5-isoquinoline (H89; a protein kinase A inhibitor) stimulated cAMP accumulation and CRE gene transcription via the β2-adrenoceptor at concentrations at which protein kinase A was inhibited, providing evidence for an alternative pathway. Propranolol, however, produced paradoxical effects; it reduced basal cAMP accumulation (via β2-mediated inverse agonism) but stimulated β2-mediated CRE gene transcription. This cannot be explained by a sequential pathway from Gs-adenylyl cyclase-cAMP to CRE binding protein phosphorylation. Both responses to propranolol were insensitive to pertussis toxin, thus excluding Gi-protein involvement. Propranolol CRE gene transcription responses were attenuated by p42/44-MAP kinase inhibitors and propranolol was also found to directly stimulate the p42/44-MAP kinase pathway. Studies of inositol phosphate accumulation and of protein kinase C or Rho kinase inhibitors on CRE-gene transcription provided no evidence for Gq/11 or G12/13 involvement. These data suggest that propranolol can simultaneously act as an inverse agonist through a Gs-coupled mechanism while stimulating the p42/44-MAP kinase pathway through an alternative G-protein-independent mechanism.

1 April 2011 in Trends in Pharmacological Sciences
Verified
Journal Article
Open access
JBJillian G. Baker
Jillian G. Baker
SHStephen Hill
Stephen Hill
RSRoger J. Summers
Roger J. Summers
Sir James Black developed β-blockers, one of the most useful groups of drugs in use today. Not only are they being used for their original purpose to treat angina and cardiac arrhythmias, but they are also effective therapeutics for hypertension, cardiac failure, glaucoma, migraine and anxiety. Recent studies suggest that they might also prove useful in diseases as diverse as osteoporosis, cancer and malaria. They have also provided some of the most useful tools for pharmacological research that have underpinned the development of concepts such as receptor subtype selectivity, agonism and inverse agonism, and ligand-directed signalling bias. This article examines how β-blockers have evolved and indicates how they might be used in the future.